<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Transfus</journal-id><journal-id journal-id-type="iso-abbrev">Blood Transfus</journal-id><journal-id journal-id-type="publisher-id">SIMTI</journal-id><journal-title-group><journal-title>Blood Transfusion</journal-title></journal-title-group><issn pub-type="ppub">1723-2007</issn><issn pub-type="epub">2385-2070</issn><publisher><publisher-name>Edizioni SIMTI - SIMTI Servizi Srl</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38063789</article-id><article-id pub-id-type="pmc">11073628</article-id>
<article-id pub-id-type="doi">10.2450/BloodTransfus.567</article-id><article-id pub-id-type="publisher-id">blt-22-198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunohematology</subject><subj-group><subject>Original Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Characterization of <italic>GYP(B-A-B)</italic> hybrid glycophorins among Thai blood donors with Mi<sup>a</sup>-positive phenotypes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nathalang</surname><given-names>Oytip</given-names></name><xref rid="af1-blt-22-198" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Khumsuk</surname><given-names>Piyathida</given-names></name><xref rid="af1-blt-22-198" ref-type="aff">1</xref><xref rid="af2-blt-22-198" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Chaibangyang</surname><given-names>Wanlapa</given-names></name><xref rid="af1-blt-22-198" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Intharanut</surname><given-names>Kamphon</given-names></name><xref rid="af1-blt-22-198" ref-type="aff">1</xref></contrib></contrib-group><aff id="af1-blt-22-198">
<label>1</label>Graduate Program in Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Rangsit Campus, Thailand</aff><aff id="af2-blt-22-198">
<label>2</label>Blood Bank, Thammasat University Hospital, Thailand</aff><author-notes><corresp id="c1-blt-22-198">Correspondence: Oytip Nathalang, e-mail: <email>oytipntl@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epreprint"><day>24</day><month>10</month><year>2023</year></pub-date><volume>22</volume><issue>3</issue><fpage>198</fpage><lpage>205</lpage><history><date date-type="received"><day>06</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>04</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>&#xA9; SIMTI Servizi Srl</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND license</ext-link></license-p></license></permissions><abstract><sec><title>Background</title><p><italic>GYPA</italic> and <italic>GYPB</italic> genes encode the antigens of the MNS blood group system carried on glycophorin A (GPA) and glycophorin B (GPB), or on a hybrid molecule of GPA and GPB. GP hybrid variants are created through unequal crossing over and gene conversion, typically from the parent genes <italic>GYPA</italic> and <italic>GYPB</italic>. In the present study, we characterized the <italic>GYP(B-A-B)</italic> hybrid variants among Thai blood donors with Mi<sup>a</sup>-positive phenotypes using PCR-based coupled to DNA sequencing techniques.</p></sec><sec><title>Materials and methods</title><p>Altogether, 1,020 samples from Thai blood donors were tested with anti-Mi<sup>a</sup> by conventional tube technique (CTT). Polymerase chain reaction with sequence-specific primer (PCR-SSP) was initially used to differentiate normal <italic>GYPB</italic>, <italic>GYP*Vw</italic> and groups of <italic>GYP*Hut</italic>, <italic>GYP*Mur</italic>, <italic>GYP*Hop</italic>, <italic>GYP*Bun</italic> and <italic>GYP*HF</italic> alleles. Subsequently, <italic>GYP(B-A-B)</italic> hybrid variants were investigated using DNA sequencing.</p></sec><sec><title>Results</title><p>Among 1,020 blood donors, 127 (12.45%) were Mi(a+) phenotypes. The comparison Mi<sup>a</sup> typing results between CTT and PCR-SSP were concordant. All Mi(a+) samples were positive with only group of <italic>GYP*Hut</italic>, <italic>GYP*Mur</italic>, <italic>GYP*Hop</italic>, <italic>GYP*Bun</italic> and <italic>GYP*HF</italic> alleles by PCR-SSP. Regarding the sequencing results, 115/1,020 (11.27%) donors carried the <italic>GYP*Mur</italic>, of which 111/1,020 (10.88%) were <italic>GYP*Mur</italic>/<italic>GYPB</italic> heterozygotes and the other 4/1,020 (0.39%) donors were <italic>GYP*Mur</italic>/G<italic>YP*Mur</italic> homozygotes. The remaining 12 donors included different <italic>GYP*Bun</italic>-like alleles; 11 of them (1.08%) were <italic>GYP*Thai</italic>/<italic>GYPB</italic> heterozygotes, and one (0.10%) was <italic>GYP*Thai II</italic>/<italic>GYPB</italic> heterozygotes. With 5.83% (119/2,040) of the total hybrid alleles, <italic>GYP*Mur</italic> was the predominant allele. The <italic>GYP*HF</italic>, <italic>GYP*Bun</italic>, <italic>GYP*Hop</italic> and <italic>GYP*Kip</italic> alleles were not observed in this study.</p></sec><sec><title>Discussion</title><p>Regarding the hybrid GP variants, a consensus of observed prevalent <italic>GYP*Mur</italic> and <italic>GYP*Bun</italic>-like alleles, respectively, was identified in the Thai population. The introduction of our strategy has allowed us to identify the zygosity for <italic>GYP</italic> hybrid variants, particularly <italic>GYP(B-A-B)</italic> hybrid genes, when antisera are unavailable and lacking adequate phenotypic features to determine GP variants.</p></sec></abstract><kwd-group><kwd>Mi<sup>a</sup> antigen</kwd><kwd>GYP(B-A-B) hybrid variants</kwd><kwd>MNS blood group system</kwd><kwd>Thais</kwd></kwd-group><funding-group><award-group><funding-source id="CS1">Thailand Science Research and Innovation Fundamental Fund and the Thammasat University Research Fund</funding-source><award-id award-type="contract" rid="CS1">TUFT36/2565</award-id></award-group></funding-group></article-meta></front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The MNS system is highly polymorphic; to date, 50 antigens have been described<xref rid="b1-blt-22-198" ref-type="bibr">1</xref>, and 36 are low-frequency antigens<xref rid="b1-blt-22-198" ref-type="bibr">1</xref>,<xref rid="b2-blt-22-198" ref-type="bibr">2</xref>. These antigens are carried on glycophorin A (GPA), glycophorin B (GPB), or hybrid GP variants, and most are produced by the hybrid formations resulting from crossing-over or gene conversion events that occurred between the highly homologous <italic>GYPA</italic>, <italic>GYPB</italic> and infrequently, <italic>GYPE</italic> within the <italic>GYP</italic> gene family. Generally, gene conversion occurs from a mechanism of double-strand break repair in which a short sequence of one gene is copied to the other during gene duplications<xref rid="b3-blt-22-198" ref-type="bibr">3</xref>. Gene conversion events between <italic>GYPA</italic> and <italic>GYPB</italic> genes result in GP hybrid alleles, including <italic>GYP(A-B</italic>), <italic>GYP(B-A-B)</italic>, <italic>GYP(A-B-A</italic>) and <italic>GYP(B-A)</italic> hybrid genes. The &#x201C;repair mechanism&#x201D; in the <italic>GYP(B-A-B)</italic> hybrids modifies the region in <italic>GYPB</italic>, corresponding to <italic>GYPA</italic> exon 3, replacing an inactive splice site sequence in <italic>GYPB</italic> with an active <italic>GYPA</italic> sequence. As a result, a hybrid protein is produced from a partial <italic>GYPB</italic> nucleotide sequence encoded by the so-called <italic>GYPB</italic> pseudoexon<xref rid="b3-blt-22-198" ref-type="bibr">3</xref>.</p>
      <p>Presently, eight hybrid GP variants express the Mi<sup>a</sup> (MNS7) antigen. Identification of the Mi<sup>a</sup>-positive phenotype, anti-Mi<sup>a</sup> could react: GP(A-B-A) hybrids, GP.Vw and GP.Hut; GP(B-A-B) hybrids, GP.Mur, GP.Hop, GP.Bun, GP.HF and GP.Kip; GP(B-A), GP.MOT red blood cells (RBCs)<xref rid="b2-blt-22-198" ref-type="bibr">2</xref>. The high prevalence of Mi<sup>a</sup> antigen presented in Southeast Asian populations is inferable to the developed anti-Mi<sup>a</sup> by alloimmunization involved in mild and severe cases of hemolytic transfusion reactions (HTRs) and hemolytic disease of the fetus and newborn (HDFN)<xref rid="b4-blt-22-198" ref-type="bibr">4</xref>&#x2013;<xref rid="b8-blt-22-198" ref-type="bibr">8</xref>. The frequency of Mi<sup>a</sup>-positive individuals ranges from 4.7 to 22.3% depending on different regions of Thailand<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>&#x2013;<xref rid="b13-blt-22-198" ref-type="bibr">13</xref>. Therefore, including the typing results of Mi<sup>a</sup> antigen in the reagent red blood cells (RBCs) is essential to detect antibodies among patients and blood donors. A related study revealed that among 94 Thai blood donors possessing the Mi<sup>a</sup>-positive phenotype, GP.Mur was the most prevalent variant (88.3%), followed by GP.Bun (11.7%) confirmed by DNA sequencing<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>.</p>
      <p>As a result, anti-Mi<sup>a</sup>, particularly anti-Mur can be detected among patients and donors. Other rare GP alloantibodies such as anti-Hop and anti-Hil might accidentally be identified among Thai patients with suspected anti-Mi<sup>a</sup> due to the incomplete patterns of antibodies reacting with Mi<sup>a</sup>-positive panel cells. Additional testing with extra panel cells of other GP phenotypes and testing the patient&#x2019;s RBCs with specific antiserum is required<xref rid="b14-blt-22-198" ref-type="bibr">14</xref>,<xref rid="b15-blt-22-198" ref-type="bibr">15</xref>. Moreover, a transfusion-dependent Thai patient had anti-E, -c, -Jk<sup>b</sup>, -S and a panreactive alloantibody, subsequently identified as anti-JENU. This antibody is specific to a high-frequency antigen on GPB and can be produced by homozygous GP.Mur individuals (also known as JENU&#x2212;). Only two of random 3,600 red cell units used in the mass screening were compatible with this patient<xref rid="b16-blt-22-198" ref-type="bibr">16</xref>.</p>
      <p>The exact identification of GP variants by serologic methods alone is challenging due to the cross-reactivity of the epitopes and the identical antigens displayed on several variations. Hence, molecular techniques have been developed to determine the hybrid genes for screening Mi<sup>a</sup>-positive donors in Thai populations, such as polymerase chain reaction with sequence-specific primer (PCR-SSP)<xref rid="b9-blt-22-198" ref-type="bibr">9</xref> and multiplex PCR<xref rid="b10-blt-22-198" ref-type="bibr">10</xref>. Interestingly, the real-time PCR melting curve technique has been implemented to differentiate the <italic>GYP*Mur</italic> allele from other Mi<sup>a</sup>-positive phenotypes<xref rid="b17-blt-22-198" ref-type="bibr">17</xref>. The <italic>GYP*Mur</italic>, <italic>GYP*Hop</italic> and <italic>GYP*Bun</italic> alleles could be identified colorimetrically using gold nanoparticle oligonucleotide probes<xref rid="b18-blt-22-198" ref-type="bibr">18</xref>. However, these techniques are still unable to discriminate between the eight hybrid GP variants expressing the Mi<sup>a</sup> antigen. A related study revealed that among 63 of 396 (15.91%) Thai blood donors with Mi<sup>a</sup>-positive phenotypes, predicted by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), exhibited a predominant <italic>GYP*Mur</italic> allele, followed by novel <italic>GYP*Bun</italic>-like (<italic>GYP*Thai</italic>) hybrid alleles<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. Therefore, this study aimed to characterize the <italic>GYP(B-A-B)</italic> hybrid variants among Thai blood donors with Mi<sup>a</sup>-positive phenotypes by PCR-based coupled to DNA sequencing techniques.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <sec>
        <title>Subjects and serological testing</title>
        <p>Blood samples in ethylenediaminetetraacetic acid disodium salt (EDTA) tubes were collected from 1,020 first-time blood donors at the Blood Bank, Thammasat University Hospital, from January to May 2023. The research protocol was approved by the Human Research Ethics Committee of Thammasat University (Science), (HREC-TUSc) Pathumthani, Thailand (COE No. 019/2564). All samples were typed for the Mi<sup>a</sup> antigen using a conventional tube technique (CTT) using human monoclonal IgM anti-Mi<sup>a</sup> (National Blood Centre, Thai Red Cross Society, Bangkok, Thailand). The Mi(a+) samples were typed for S and s antigens by indirect antiglobulin test (IAT) using human IgG anti-S and anti-s (CE-Immundiagnostika GmbH, Eschelbronn, Germany). To confirm the presence of S and s antigens; the direct antiglobulin test (DAT) was performed to rule out false positive results. The IAT and DAT by CTT were performed according to the manufacturer instructions.</p>
      </sec>
      <sec>
        <title>Extracting DNA</title>
        <p>Genomic DNA was isolated from the samples using the DNeasy Blood &amp; Tissue Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer instructions, then stored at &#x2212;20&#xB0;C before further analysis.</p>
      </sec>
      <sec>
        <title>Molecular typing by PCR-SSP</title>
        <p>The PCR-SSP was initially performed to confirm the presence or absence of Mi<sup>a</sup>, S and s antigens at the molecular level. Specific PCR amplification of <italic>GYPB*S</italic> and <italic>GYPB*s</italic> alleles in the <italic>GYPB</italic> gene was performed. A co-amplification of the human growth hormone (<italic>HGH</italic>) gene was run as the internal control. The PCR amplification conditions and primers used were similar to those described<xref rid="b20-blt-22-198" ref-type="bibr">20</xref>. Additionally, two primer sets targeting the <italic>GYP(A-B-A)</italic> and <italic>GYP(B-A-B)</italic> hybrid genes were used along with <italic>HGH</italic>-specific control primers. The fragments of the sets of <italic>GYP*Hut, GYP*Mur</italic>, <italic>GYP*Hop</italic>, <italic>GYP*Bun</italic> and <italic>GYP*HF</italic>, and the fragment of the other set of <italic>GYP*Vw</italic> were amplified to identify possibly predicted GP variants in conditions previously described<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>.</p>
      </sec>
      <sec>
        <title>Identifying <italic>GYP(B-A-B)</italic> hybrid alleles by DNA sequencing</title>
        <p>A genomic region in <italic>GYPB</italic> exons 2 and 3, was targeted by PCR amplification to characterize <italic>GYP(B-A-B)</italic> hybrid alleles. Regarding inserting different portions of the active GYPA sequences, it enabled us to identify the <italic>GYP*Mur</italic>, <italic>GYP*Bun</italic>, <italic>GYP*Bun-like</italic> (<italic>GYP*Thai</italic> and <italic>GYP*Thai II</italic>), <italic>GYP*Hop</italic>, <italic>GYP*HF</italic>, and <italic>GYP*Kip</italic> variants using the method of DNA sequencing. The PCR amplification reaction system for the targeted region amplification was as follows: template DNA (50 ng/&#x3BC;L) 3 &#x3BC;L, forward primer (GYPB-2564-F: 5&#x2032;-CCCTAGCAGATGGAGACACTG-3&#x2032;) 3 &#x3BC;L, reverse primer (GYPB-2564-R: 5&#x2032;-CTTTGTCTTTACAATTTCGTGTGAA-3&#x2032;) 3 &#x3BC;L, 2&#xD7; PCR reaction mixture (Phusion High-Fidelity PCR Master Mix, New England BioLabs, MA, USA) 20 &#x3BC;L, double distilled water 11 &#x3BC;L, for a total volume of 40 &#x3BC;L at 98&#xB0;C; initial denaturation for 30 s, 98&#xB0;C for 10 s and 68&#xB0;C for 1 min, for 10 cycles, 98&#xB0;C for 10 s, 68&#xB0;C for 50 s and 72&#xB0;C for 1 min 30 s, for 25 cycles, and finally 72&#xB0;C for 5 min. Thereafter, amplification of PCR products was separated on a 1.5% agarose gel containing SYBR Safe DNA Gel Stain (Invitrogen, Paisley, UK), electrophoresed in 1&#xD7; TBE buffer at 100 volts, and visualized under a blue light transilluminator. The PCR bands were cut and purified, following the instructions provided with a gel extraction kit (GeneJET Gel Extraction Kit, Thermo Scientific, Waltham, MA, USA) and the eluted fragments were then sequenced by next generation sequencing-based technology on the Illumina Platform (BTSeqTM Services, Celemics Inc., Seoul, Korea). The sequencing results were analyzed and compared with those in GenBank (GenBank reference: <italic>GYPA</italic>, NG_007470.3; <italic>GYPB</italic>, NG_007483.2; <italic>GYPE</italic>, NG_009173.1) with BioEdit software (UNT Computing for Arts &amp; Sciences, Denton, TX, USA).</p>
      </sec>
      <sec>
        <title>Statistical analysis</title>
        <p>The prevalence of the observed variant alleles was described using descriptive statistics and expressed in numbers and percentages. All statistical analyses were conducted using SPSS, Version 16.0 (SPSS Inc., Chicago, IL, USA).</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <sec>
        <title>Serological testing and PCR-SSP</title>
        <p>A total of 1,020 blood samples were tested using anti-Mi<sup>a</sup> by CTT, 127 (12.45%) donor samples were Mi(a+) phenotypes. According to the manufacturer instructions, anti-Mi<sup>a</sup> could recognize and bind to RBCs of the Mi<sup>a</sup>-positive phenotypes consisting of GP.Vw, GP.Hut, GP.Mur, GP.Hop, GP.Bun and GP.HF. Moreover, each sample was subjected to PCR-SSP analysis. All Mi(a+) samples were positive with only the set of primers specific for <italic>GYP*Hut</italic>, <italic>GYP*Mur, GYP*Hop, GYP*Bun</italic> and <italic>GYP*HF</italic>. No <italic>GYP*Vw</italic> allele was identified using PCR-SSP. In contrast, 893 Mi(a&#x2212;) samples showed negative results for both sets of primers specific for <italic>GYP*Hut</italic>, <italic>GYP*Mur, GYP*Hop, GYP*Bun</italic>, <italic>GYP*HF</italic> and <italic>GYP*Vw</italic>. In all samples tested, the comparison results between CTT and PCR-SSP were concordant. Of those 127 Mi<sup>a</sup>-positive donors, the most frequent phenotype was S&#x2212;s+ (97.64%) followed by S+s+ (2.36%). The S+s&#x2212; phenotype was not found. In addition, <italic>GYPB*S</italic> and <italic>GYPB*s</italic> allele detections using PCR-SSP were tested and the phenotyping, and genotyping results were 100% concordant (<xref rid="tI-blt-22-198" ref-type="table">Table I</xref>).</p>
      </sec>
      <sec>
        <title>Identifying <italic>GYP(B-A-B)</italic> hybrid alleles by DNA sequencing</title>
        <p>The differences in nucleotide positions of <italic>GYPA</italic>, <italic>GYPB</italic>, and <italic>GYP(B-A-B)</italic> hybrids are represented in <xref rid="f1-blt-22-198" ref-type="fig">Figure 1</xref>. The <italic>GYP(B-A-B)</italic> hybrid genes comprise <italic>GYP*Mur</italic>, <italic>GYP*Bun</italic>, <italic>GYP*Bun-like</italic> (<italic>GYP*Thai</italic> and <italic>GYP*Thai II</italic>), <italic>GYP*Hop</italic>, <italic>GYP*HF</italic> and <italic>GYP*Kip</italic> variants. Sequencing results have been characterized by the insertion of various regions of the active <italic>GYPA</italic> sequences. The <italic>GYP*HF</italic> allele revealed the longest <italic>GYPA</italic> insert of 161 nucleotides that code for 24 amino acids, whereas the shorter insertion of the <italic>GYPA</italic> segment presents in the <italic>GYP*Thai</italic> allele. The <italic>GYP*Thai</italic> allele has a minimum <italic>GYPA</italic>-derived sequence insert of 22 nucleotides and a maximum of 53 nucleotides. The <italic>GYP*Thai II</italic> allele has a minimum insert of 46 nucleotides and a maximum of 117 nucleotides. Moreover, sequencing results revealed an insertion of 118 <italic>GYPA</italic>-derived nucleotides, encoding nine amino acids in the <italic>GYP*Mur</italic> allele. The <italic>GYP*Bun</italic>, <italic>GYP*Hop</italic> and <italic>GYP*Kip</italic> alleles have a <italic>GYPA</italic> insert of 131, 131 and 108 nucleotides, carrying the shortest GPA insert of 7 amino acids. The SNP encoded by exon 4, at c.236T/C (analogous to the <italic>GYPB*S</italic>/<italic>GYPB*s</italic> defining <italic>GYPB</italic> c.143T/C) identifies <italic>GYP*Hop</italic> (c.236T) from the <italic>GYP*Bun</italic> and <italic>GYP*Kip</italic> (c.236C) alleles. The <italic>GYP*Bun</italic> and <italic>GYP*Kip</italic> alleles differ by a SNP (rs34498102), c.209A/C (<xref rid="f1-blt-22-198" ref-type="fig">Figure 1</xref>).</p>
        <p>DNA sequencing analysis results are demonstrated in <xref rid="tII-blt-22-198" ref-type="table">Table II</xref>. All 893 Mi(a&#x2212;) samples were normal <italic>GYPB</italic> homozygote. Of the other 127 Mi(a+) <italic>GYP(B-A-B)</italic> hybrid samples, 115/1,020 (11.27%) donors carried the <italic>GYP*Mur</italic>, of which 111/1,020 (10.88%) were <italic>GYP*Mur</italic>/<italic>GYPB</italic> heterozygotes and the other 4/1,020 (0.39%) donors were <italic>GYP*Mur</italic>/<italic>GYP*Mur</italic> homozygotes. The remaining 12 donors included different <italic>GYP*Bun</italic>-like alleles; 11 of them (1.08%) were <italic>GYP*Thai</italic>/<italic>GYPB</italic> heterozygotes, and one (0.10%) was <italic>GYP*Thai II</italic>/<italic>GYPB</italic> heterozygotes. The <italic>GYP*Mur</italic> allele was the predominant hybrid allele and was observed in 119/2,040 (5.83%) alleles. The <italic>GYP*HF, GYP*Bun</italic>, <italic>GYP*Hop</italic> and <italic>GYP*Kip</italic> alleles were not observed in this study.</p>
      </sec>
      <sec>
        <title>Estimating the risk for Mi<sup>a</sup> alloimmunization among Thai and other populations</title>
        <p>The estimated risk of Mi<sup>a</sup> alloimmunization was obtained by multiplying the probability of being predicted by the Mi<sup>a</sup>-negative phenotype frequency by the predicted Mi<sup>a</sup>-positive phenotype frequency<xref rid="b20-blt-22-198" ref-type="bibr">20</xref>. The frequencies of predicted Mi<sup>a</sup> phenotypes in the Thai population were compared with related studies among Thai and other Asian populations. From low to high sorting, the Indonesian population<xref rid="b21-blt-22-198" ref-type="bibr">21</xref> indicated the lowest risk of Mi<sup>a</sup> alloimmunization, followed by Taiwanese<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>, southern Thai<xref rid="b13-blt-22-198" ref-type="bibr">13</xref>, Vietnamese<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>, southern Han Chinese<xref rid="b22-blt-22-198" ref-type="bibr">22</xref>, Filipino<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>, central Thai<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>, Chinese (Guangzhou)<xref rid="b23-blt-22-198" ref-type="bibr">23</xref>, Thai (this study) and northern Thai<xref rid="b10-blt-22-198" ref-type="bibr">10</xref> populations, respectively (<xref rid="tIII-blt-22-198" ref-type="table">Table III</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Low frequency antigens of the MNS blood group system, especially the Mi<sup>a</sup> antigen, are clinically relevant in Southeast Asian populations owing to the high prevalence of Mi<sup>a</sup> alloimmunization and HTRs and HDFN cases<xref rid="b4-blt-22-198" ref-type="bibr">4</xref>&#x2013;<xref rid="b8-blt-22-198" ref-type="bibr">8</xref>. Routinely, testing RBCs among patients and donors with anti-Mi<sup>a</sup> is convenient and can identify Mi<sup>a</sup>-positive and Mi<sup>a</sup>-negative individuals. However, serological testing limitations include unavailable specific antiserum to determine eight hybrid GP variants showing Mi<sup>a</sup>-positive phenotypes. Among Thai patients with suspected anti-Mi<sup>a</sup>, the inconclusive patterns of agglutination reactions with Mi<sup>a</sup>-positive panel cells required extra cells with known GP subclasses to determine antibody specificities such as anti-Hop and anti-Hil<xref rid="b14-blt-22-198" ref-type="bibr">14</xref>,<xref rid="b15-blt-22-198" ref-type="bibr">15</xref>. Further testing using molecular techniques are beneficial in clarifying the frequencies of GP subclasses in populations<xref rid="b17-blt-22-198" ref-type="bibr">17</xref>&#x2013;<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>,<xref rid="b22-blt-22-198" ref-type="bibr">22</xref>&#x2013;<xref rid="b24-blt-22-198" ref-type="bibr">24</xref>.</p>
      <p>In this study, we initially screened GP variants using human monoclonal anti-Mi<sup>a</sup> to distinguish between Mi<sup>a</sup>-positive and Mi<sup>a</sup>-negative phenotypes, and 127 of 1,020 blood samples were Mi<sup>a</sup>-positive representing a frequency of 12.45%, which is consistent with related studies in central Thai blood donor populations<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>,<xref rid="b25-blt-22-198" ref-type="bibr">25</xref>. PCR-based coupled to DNA sequencing techniques were subsequently performed to characterize the <italic>GYP*(B-A-B)</italic> hybrid GP variants among blood donors with Mi<sup>a</sup>-positive phenotypes. The PCR-SSP testing results in 1,020 samples agreed with the serological testing results. Moreover, the <italic>GYP*Vw</italic> allele was not found using PCR-SSP, similar to related studies in Thai populations<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>,<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. The occurrence of GP.Vw was reported at 1.43% in Southern Switzerland and 0.057% in Caucasian populations<xref rid="b26-blt-22-198" ref-type="bibr">26</xref>.</p>
      <p>Among the 127 Mi<sup>a</sup>-positive donors from the initial screening using the serological test and PCR-SSP, all samples were further sequenced to determine the <italic>GYP(B-A-B)</italic> hybrids. The <italic>GYP*Mur</italic> hybrid allele was the most prevalent (5.83%), followed by <italic>GYP*Thai</italic> (0.59%) consisting of <italic>GYP*Thai</italic> and <italic>GYP*Thai II</italic>. A DNA sequencing technique employed to authenticate all 893 Mi<sup>a</sup>-negative donors identified normal <italic>GYPB</italic> homozygotes. The <italic>GYP*HF, GYP*Bun</italic>, <italic>GYP*Hop</italic> and <italic>GYP*Kip</italic> alleles were not found in this study. The related studies of GP. subclasses of Mi<sup>a</sup>-positive Thai blood donors revealed that GP.Mur was the most common (93.0%) and the other was GP.Bun (7.0%)<xref rid="b25-blt-22-198" ref-type="bibr">25</xref>,<xref rid="b27-blt-22-198" ref-type="bibr">27</xref>. Thereafter, the other study determined GP. subclasses of Mi<sup>a</sup>-positive donors using DNA sequencing confirming that GP.Mur and GP.Bun were observed in 88.0 and 12.0%, respectively<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>. A recent study reported the <italic>GYP*Mur</italic> and <italic>GYP*Bun</italic>-like &#x2013;<italic>GYP*Thai</italic> and <italic>GYP*Thai II</italic>&#x2013;alleles were identified in 88.9 and 11.1%, respectively<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. All the above mentioned studies describe multiple concordance observations in which the high prevalence of GP.Mur and GP.Bun was classified among Thais. In this study a similarity in predicted GP.Mur and GP.Bun frequencies was 90.6% (115/127) and 9.4% (12/127), in rank. In addition, we also identified <italic>GYP*Bun</italic>-like alleles which was consistent with the study reported by Jongruamklang and colleagues<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. However, the <italic>GYP*Bun</italic>-like alleles with a shorter insertion of noncoding <italic>GYPA</italic> sequences spanning intron 3 (<xref rid="f1-blt-22-198" ref-type="fig">Figure 1</xref>) remain sufficient to predict the expression of the GP.Bun hybrid protein.</p>
      <p>The serologic and PCR-SSP testing results among 127 Mi<sup>a</sup>-positive donors confirmed that the S&#x2212;s+ phenotype was the most common (97.6%), and the other three S+s+ individuals (2.4%) were <italic>GYP*Mur</italic>/<italic>GYPB</italic>. A related study reported by Jongruamklang and colleagues revealed that 51 of <italic>GYP*Mur</italic>/<italic>GYPB</italic> individuals (100%) had S&#x2212;s+ phenotype<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. Regarding the qualitatively and semiquantitatively altered s antigen in GP. hybrids, the study demonstrated that the s antigen carried by GP.Mur or GP.Bun was not detected by IgM monoclonal anti-s (P3BER), but the use of two IgG anti-s showed improved reactivity. We have also detected the s antigen carried by these hybrids without any discrepancies in typing results obtained by serological and molecular approaches, supporting the recent report that IgG anti-s (polyclonal) used in our study could discriminate the s phenotypes<xref rid="b19-blt-22-198" ref-type="bibr">19</xref>. In addition to the report of alloanti-JENU, a Thai patient carrying JENU&#x2212;, <italic>GYP*Mur</italic>/<italic>GYP*Mur</italic> homozygote lacked normal GPB and had been alloimmunized by exposure to RBCs from donors expressing GP hybrid heterozygotes (Mi<sup>a</sup>-positive) or normal GPB (Mi<sup>a</sup>-negative)<xref rid="b16-blt-22-198" ref-type="bibr">16</xref>. In this study, 115 donors possessed <italic>GYP*Mur</italic>, of which four samples were homozygous <italic>GYP*Mur</italic>/<italic>GYP*Mur</italic>. The probability of finding alloanti-JENU in JENU&#x2212; individuals may be prone to observe in Thai patient populations, especially in chronic transfusion therapy. These patients could produce alloantibodies with multiple antibody specificities and had trouble searching for compatible blood units by underlying unidentified alloantibodies (perhaps anti-JENU). Therefore, our genotyping strategy using PCR-based coupled to DNA sequencing techniques plays a role in identifying JENU&#x2212; patients and donors, as well as providing additional reagent RBCs to determine hidden unidentified anti-JENU. Moreover, the estimated risk of Mi<sup>a</sup> alloimmunization of central Thais was compared with two Thai populations and another population<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>,<xref rid="b10-blt-22-198" ref-type="bibr">10</xref>,<xref rid="b13-blt-22-198" ref-type="bibr">13</xref>,<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>&#x2013;<xref rid="b23-blt-22-198" ref-type="bibr">23</xref>. For the highest risk of Mi<sup>a</sup> alloimmunization in northern Thais (0.173), detecting anti-JENU proneness increased in this population. Similar expectations of anti-JENU production may be observed in Chinese populations.</p>
      <p>The advantages of using PCR-based coupled to DNA sequencing techniques are first differentiation of Mi<sup>a</sup>-positive and Mi<sup>a</sup>-negative samples. Second, the <italic>GYP*Vw</italic>, <italic>GYP(A-B-A)</italic> variant can be excluded from <italic>GYP*Hut</italic>, <italic>GYP*Mur, GYP*Hop, GYP*Bun</italic> and <italic>GYP*HF</italic>. Third, the discrimination of those alleles in <italic>GYP(B-A-B)</italic> variants can be identified by DNA sequencing, leading to determining the zygosity for <italic>GYP</italic> hybrid variants. In addition, determining GP.Mur homozygote individuals is beneficial in identifying the antibodies related to anti-Mi<sup>a</sup>: (1) weak anti-Mi<sup>a</sup> using reagent panel cells from GP.Mur homozygotes<xref rid="b28-blt-22-198" ref-type="bibr">28</xref>,<xref rid="b29-blt-22-198" ref-type="bibr">29</xref>, (2) anti-U produced by U+ and GP.Mur homozygous individuals<xref rid="b30-blt-22-198" ref-type="bibr">30</xref> and (3) anti-JENU triggered by GP.Mur homozygous individuals<xref rid="b16-blt-22-198" ref-type="bibr">16</xref>.</p>
      <p>The limitations of this study using PCR-based coupled DNA sequencing techniques included <italic>GYP(A-B-A)</italic> variant with Mi<sup>a</sup>-positive hybrid GP, <italic>GYP*Hut</italic> allele could not be differentiated; however, the distribution of the GP.Hut was rare (0.04%) in the Thai population, as reported by Chandanayingyong and colleagues<xref rid="b31-blt-22-198" ref-type="bibr">31</xref>. This allele warrants further studies to determine DNA sequencing in larger population samples. Even though the Mi<sup>a</sup>-positive phenotype whose <italic>GYP*MOT</italic> allele, a <italic>GYP(B-A)</italic> hybrid gene could not be determined, it has been recently discoverd only in one Japanese donor<xref rid="b2-blt-22-198" ref-type="bibr">2</xref>,<xref rid="b32-blt-22-198" ref-type="bibr">32</xref>.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSIONS</title>
      <p>We have characterized the <italic>GYP(B-A-B)</italic> variant genes in Mi<sup>a</sup>-positive Thai donors by PCR-based coupled with DNA sequencing techniques. For GP variant alleles, a consensus of observed prevalent <italic>GYP*Mur</italic> and <italic>GYP*Bun-</italic>like alleles, respectively, was identified in the Thai population. The introduction of our strategy has allowed us to identify the zygosity for <italic>GYP</italic> hybrid variants, particularly <italic>GYP(B-A-B)</italic> hybrid genes, when antisera are unavailable and lacking adequate phenotypic features to determine GP variants.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn1-blt-22-198">
        <p><bold>ETHICAL CONSIDERATION:</bold> This study was approved by the Human Research Ethics Committee of Thammasat University (Science), (HREC-TUSc) Pathumthani, Thailand (COE No. 019/2564). The research was conducted ethically, with all study procedures being performed in accordance with the requirements of the World Medical Association&#x2019;s Declaration of Helsinki.</p>
        <p>Written informed consent was obtained from each participant/patient for study participation and data publication.</p>
      </fn>
      <fn id="fn2-blt-22-198" fn-type="COI-statement">
        <p><bold>AUTHORS&#x2019; CONTRIBUTIONS:</bold> ON contributed to the study design, analyzed the data and wrote and reviewed the paper. PK collected samples, performed serologic and molecular tests. WC wrote and reviewed the paper. KI standardized the methodology, analyzed the results, wrote and reviewed the paper. <italic>The Authors declare no conflicts of interest.</italic></p>
      </fn>
      <fn id="fn3-blt-22-198">
        <p><bold>FUNDING:</bold> This research was funded by the Thailand Science Research and Innovation Fundamental Fund and the Thammasat University Research Fund, contract No. TUFT36/2565.</p>
      </fn>
      <fn id="fn4">
        <p>Commented by doi 10.2450/BloodTransfus.763</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1-blt-22-198">
        <label>1</label>
        <element-citation publication-type="book">
<collab>International Society of Blood Transfusion</collab>
<source>Red Cell Immunogenetics and Blood Group Terminology</source>
<publisher-name>ISBT</publisher-name>
<comment>Available at: <ext-link xlink:href="https://www.isbtweb.org/resource/tableofbloodgroupsystems.html./" ext-link-type="uri">https://www.isbtweb.org/resource/tableofbloodgroupsystems.html./</ext-link></comment>
<date-in-citation content-type="access-date">Accessed on 31/03/2023</date-in-citation>
</element-citation>
      </ref>
      <ref id="b2-blt-22-198">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez</surname><given-names>GH</given-names></name><name><surname>Hyland</surname><given-names>CA</given-names></name><name><surname>Flower</surname><given-names>RL</given-names></name></person-group>
<article-title>Glycophorins and the MNS blood group system: a narrative review</article-title>
<source>Ann Blood</source>
<year>2021</year>
<volume>6</volume>
<fpage>39</fpage>
<pub-id pub-id-type="doi">10.21037/aob-21-9</pub-id>
</element-citation>
      </ref>
      <ref id="b3-blt-22-198">
        <label>3</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Daniels</surname><given-names>G</given-names></name></person-group>
<source>Human Blood Groups</source>
<edition>3rd ed</edition>
<publisher-loc>West Sussex, UK</publisher-loc>
<publisher-name>Wiley-Blackwell</publisher-name>
<year>2013</year>
</element-citation>
      </ref>
      <ref id="b4-blt-22-198">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heathcote</surname><given-names>DJ</given-names></name><name><surname>Carroll</surname><given-names>TE</given-names></name><name><surname>Flower</surname><given-names>RL</given-names></name></person-group>
<article-title>Sixty years of antibodies to MNS system hybrid glycophorins: what have we learned?</article-title>
<source>Transfus Med Rev</source>
<year>2011</year>
<volume>25</volume>
<fpage>111</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/j.tmrv.2010.11.003</pub-id>
<pub-id pub-id-type="pmid">21345645</pub-id>
</element-citation>
      </ref>
      <ref id="b5-blt-22-198">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Broadberry</surname><given-names>RE</given-names></name></person-group>
<article-title>An intravascular hemolytic transfusion reaction due to anti-&#x2019;Mi(a)&#x2019; in Taiwan</article-title>
<source>Vox Sang</source>
<year>1994</year>
<volume>67</volume>
<fpage>320</fpage>
<pub-id pub-id-type="doi">10.1111/j.1423-0410.1994.tb01262.x</pub-id>
<pub-id pub-id-type="pmid">7863635</pub-id>
</element-citation>
      </ref>
      <ref id="b6-blt-22-198">
        <label>6</label>
        <element-citation publication-type="webpage">
<trans-title xml:lang="en">Delayed hemolytic transfusion reaction due to anti-Mi<sup>a</sup></trans-title>
<source>Thai Journal of Hematology and Transfusion Medicine</source>
<comment>Available at: <ext-link xlink:href="http://www.tsh.or.th/file_upload/files/v6%20n4%20289.pdf" ext-link-type="uri">http://www.tsh.or.th/file_upload/files/v6%20n4%20289.pdf</ext-link></comment>
<date-in-citation content-type="access-date">Accessed on 06/06/2023</date-in-citation>
<comment>[in Thai]</comment>
</element-citation>
      </ref>
      <ref id="b7-blt-22-198">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>CK</given-names></name><name><surname>Mak</surname><given-names>KH</given-names></name><name><surname>Szeto</surname><given-names>SC</given-names></name><name><surname>Poon</surname><given-names>KH</given-names></name><name><surname>Yuen</surname><given-names>CM</given-names></name><name><surname>Chan</surname><given-names>NK</given-names></name><etal/></person-group>
<article-title>First case of haemolytic disease of the newborn due to anti-Mur in Hong Kong</article-title>
<source>Clin Lab Haematol</source>
<year>1996</year>
<volume>18</volume>
<fpage>19</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2257.1996.tb00731.x</pub-id>
<pub-id pub-id-type="pmid">9118598</pub-id>
</element-citation>
      </ref>
      <ref id="b8-blt-22-198">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mallari</surname><given-names>RA</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Powers</surname><given-names>RJ</given-names></name><name><surname>Pandipati</surname><given-names>S</given-names></name><name><surname>Bensing</surname><given-names>KM</given-names></name><name><surname>Biese</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Fetal inheritance of GP*Mur causing severe HDFN in an unrecognized case of maternal alloimmunization</article-title>
<source>Transfusion</source>
<year>2020</year>
<volume>60</volume>
<fpage>870</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="doi">10.1111/trf.15709</pub-id>
<pub-id pub-id-type="pmid">32056233</pub-id>
</element-citation>
      </ref>
      <ref id="b9-blt-22-198">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palacajornsuk</surname><given-names>P</given-names></name><name><surname>Nathalang</surname><given-names>O</given-names></name><name><surname>Tantimavanich</surname><given-names>S</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>ME</given-names></name></person-group>
<article-title>Detection of MNS hybrid molecules in the Thai population using PCR-SSP technique</article-title>
<source>Transfus Med</source>
<year>2007</year>
<volume>17</volume>
<fpage>169</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-3148.2007.00747.x</pub-id>
<pub-id pub-id-type="pmid">17561857</pub-id>
</element-citation>
      </ref>
      <ref id="b10-blt-22-198">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Intharanut</surname><given-names>K</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name><name><surname>Nathalang</surname><given-names>S</given-names></name><name><surname>Leetrakool</surname><given-names>N</given-names></name><name><surname>Nathalang</surname><given-names>O</given-names></name></person-group>
<article-title>Red cell genotyping by multiplex PCR identifies antigen-matched blood units for transfusion-dependent Thai patients</article-title>
<source>Transfus Med Hemother</source>
<year>2017</year>
<volume>44</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1159/000471886</pub-id>
<pub-id pub-id-type="pmid">29070981</pub-id>
</element-citation>
      </ref>
      <ref id="b11-blt-22-198">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jongruamklang</surname><given-names>P</given-names></name><name><surname>Gassner</surname><given-names>C</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>Kummasook</surname><given-names>A</given-names></name><name><surname>Darlison</surname><given-names>M</given-names></name><name><surname>Boonlum</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of 36 blood group alleles among 396 Thai samples reveals region-specific variants</article-title>
<source>Transfusion</source>
<year>2018</year>
<volume>58</volume>
<fpage>1752</fpage>
<lpage>1762</lpage>
<pub-id pub-id-type="doi">10.1111/trf.14624</pub-id>
<pub-id pub-id-type="pmid">29656499</pub-id>
</element-citation>
      </ref>
      <ref id="b12-blt-22-198">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romphruk</surname><given-names>AV</given-names></name><name><surname>Butryojantho</surname><given-names>C</given-names></name><name><surname>Jirasakonpat</surname><given-names>B</given-names></name><name><surname>Junta</surname><given-names>N</given-names></name><name><surname>Srichai</surname><given-names>S</given-names></name><name><surname>Puapairoj</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Phenotype frequencies of Rh (C, c, E, e), M, Mi<sup>a</sup> and Kidd blood group systems among ethnic Thai blood donors from the north-east of Thailand</article-title>
<source>Int J Immunogenet</source>
<year>2019</year>
<volume>46</volume>
<fpage>160</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1111/iji.12420</pub-id>
<pub-id pub-id-type="pmid">30884143</pub-id>
</element-citation>
      </ref>
      <ref id="b13-blt-22-198">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khosidworachet</surname><given-names>W</given-names></name><name><surname>Mitundee</surname><given-names>S</given-names></name><name><surname>Intharanut</surname><given-names>K</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name><name><surname>Nathalang</surname><given-names>O</given-names></name></person-group>
<article-title>Frequencies of predicted Mi<sup>a</sup> antigen among southern Thai blood donors</article-title>
<source>J Southeast Asian Med Res</source>
<year>2021</year>
<volume>6</volume>
<fpage>e107</fpage>
<comment>Available at: <ext-link xlink:href="https://www.jseamed.org/index.php/jseamed" ext-link-type="uri">https://www.jseamed.org/index.php/jseamed</ext-link></comment>
<date-in-citation content-type="access-date">Accessed on 06/06/2023</date-in-citation>
</element-citation>
      </ref>
      <ref id="b14-blt-22-198">
        <label>14</label>
        <element-citation publication-type="webpage">
<trans-title xml:lang="en">Anti-Hop, a rare antibody of Miltenberger subclass in a Thai patient: a case report</trans-title>
<source>Journal of Hematology and Transfusion Medicine</source>
<comment>Available at: <ext-link xlink:href="http://www.tsh.or.th/file_upload/files/08%20Anti-Hop.pdf" ext-link-type="uri">http://www.tsh.or.th/file_upload/files/08%20Anti-Hop.pdf</ext-link></comment>
<date-in-citation content-type="access-date">Accessed on 06/06/2023</date-in-citation>
<comment>[In Thai]</comment>
</element-citation>
      </ref>
      <ref id="b15-blt-22-198">
        <label>15</label>
        <element-citation publication-type="webpage">
<trans-title xml:lang="en">Identification of a rare alloanti-GP.Hil (anti-MNS20) in a Thai patient</trans-title>
<source>Journal of Hematology and Transfusion Medicine</source>
<comment>Available at: <ext-link xlink:href="http://www.tsh.or.th/file_upload/files/20161229%2009%20Identification%20of%20a%20rare%20%5BCase%20report%5D.pdf" ext-link-type="uri">http://www.tsh.or.th/file_upload/files/20161229%2009%20Identification%20of%20a%20rare%20%5BCase%20report%5D.pdf</ext-link></comment>
<date-in-citation content-type="access-date">Accessed on 06/06/2023</date-in-citation>
<comment>[In Thai]</comment>
</element-citation>
      </ref>
      <ref id="b16-blt-22-198">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez</surname><given-names>GH</given-names></name><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Liew</surname><given-names>YW</given-names></name><name><surname>Kupatawintu</surname><given-names>P</given-names></name><name><surname>Emthip</surname><given-names>M</given-names></name><name><surname>Hyland</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>An alloantibody in a homozygous <italic>GYP*Mur</italic> individual defines JENU (MNS49), a new high-frequency antigen on glycophorin B</article-title>
<source>Transfusion</source>
<year>2017</year>
<volume>57</volume>
<fpage>716</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="doi">10.1111/trf.13952</pub-id>
<pub-id pub-id-type="pmid">27917500</pub-id>
</element-citation>
      </ref>
      <ref id="b17-blt-22-198">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vongsakulyanon</surname><given-names>A</given-names></name><name><surname>Kitpoka</surname><given-names>P</given-names></name><name><surname>Kunakorn</surname><given-names>M</given-names></name><name><surname>Srikhirin</surname><given-names>T</given-names></name></person-group>
<article-title>Miltenberger blood group typing by real-time polymerase chain reaction (qPCR) melting curve analysis in Thai population</article-title>
<source>Transfus Med</source>
<year>2015</year>
<volume>25</volume>
<fpage>393</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1111/tme.12265</pub-id>
<pub-id pub-id-type="pmid">26681402</pub-id>
</element-citation>
      </ref>
      <ref id="b18-blt-22-198">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vongsakulyanon</surname><given-names>A</given-names></name><name><surname>Pipatpanukul</surname><given-names>C</given-names></name><name><surname>Kitpoka</surname><given-names>P</given-names></name><name><surname>Kunakorn</surname><given-names>M</given-names></name><name><surname>Srikhirin</surname><given-names>T</given-names></name></person-group>
<article-title>Colorimetric Detection by Gold Nanoparticle DNA Probes for Miltenberger Series (GP.Mur, GP.Hop, and GP.Bun) Identification</article-title>
<source>J Clin Lab Anal</source>
<year>2016</year>
<volume>30</volume>
<fpage>880</fpage>
<lpage>887</lpage>
<pub-id pub-id-type="doi">10.1002/jcla.21951</pub-id>
<pub-id pub-id-type="pmid">27075240</pub-id>
</element-citation>
      </ref>
      <ref id="b19-blt-22-198">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jongruamklang</surname><given-names>P</given-names></name><name><surname>Grimsley</surname><given-names>S</given-names></name><name><surname>Thornton</surname><given-names>N</given-names></name><name><surname>Robb</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>ML</given-names></name><name><surname>Storry</surname><given-names>JR</given-names></name></person-group>
<article-title>Characterization of <italic>GYP*Mur</italic> and novel <italic>GYP*Bun</italic>-like hybrids in Thai blood donors reveals a qualitatively altered s antigen</article-title>
<source>Vox Sang</source>
<year>2020</year>
<volume>115</volume>
<fpage>472</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1111/vox.12909</pub-id>
<pub-id pub-id-type="pmid">32201961</pub-id>
</element-citation>
      </ref>
      <ref id="b20-blt-22-198">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nathalang</surname><given-names>O</given-names></name><name><surname>Ang</surname><given-names>RM</given-names></name><name><surname>Kurin</surname><given-names>B</given-names></name><name><surname>Limprasert</surname><given-names>S</given-names></name><name><surname>Mitundee</surname><given-names>S</given-names></name><name><surname>Leetrakool</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Predicted S and s phenotypes from genotyping results among Thai populations to prevent transfusion-induced alloimmunization risks</article-title>
<source>Transfus Apher Sci</source>
<year>2018</year>
<volume>57</volume>
<fpage>582</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1016/j.transci.2018.07.019</pub-id>
<pub-id pub-id-type="pmid">30078741</pub-id>
</element-citation>
      </ref>
      <ref id="b21-blt-22-198">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Chao</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>TY</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>YS</given-names></name></person-group>
<article-title>Assessing the frequencies of GP.Mur (Mi.III) in several Southeast Asian populations by PCR typing</article-title>
<source>Transfus Apher Sci</source>
<year>2013</year>
<volume>49</volume>
<fpage>370</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1016/j.transci.2013.05.011</pub-id>
<pub-id pub-id-type="pmid">23756267</pub-id>
</element-citation>
      </ref>
      <ref id="b22-blt-22-198">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Lopez</surname><given-names>GH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Genotyping analysis of MNS blood group GP(B-A-B) hybrid glycophorins in the Chinese Southern Han population using a high-resolution melting assay</article-title>
<source>Transfusion</source>
<year>2018</year>
<volume>58</volume>
<fpage>1763</fpage>
<lpage>1771</lpage>
<pub-id pub-id-type="doi">10.1111/trf.14641</pub-id>
<pub-id pub-id-type="pmid">29897102</pub-id>
</element-citation>
      </ref>
      <ref id="b23-blt-22-198">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Shan</surname><given-names>ZG</given-names></name><name><surname>Flower</surname><given-names>RL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>JZ</given-names></name><name><surname>Luo</surname><given-names>GP</given-names></name><etal/></person-group>
<article-title>The distribution of MNS hybrid glycophorins with Mur antigen expression in Chinese donors including identification of a novel GYP.Bun allele</article-title>
<source>Vox Sang</source>
<year>2016</year>
<volume>111</volume>
<fpage>308</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1111/vox.12421</pub-id>
<pub-id pub-id-type="pmid">27232276</pub-id>
</element-citation>
      </ref>
      <ref id="b24-blt-22-198">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez</surname><given-names>GH</given-names></name><name><surname>Wilson</surname><given-names>B</given-names></name><name><surname>Turner</surname><given-names>RM</given-names></name><name><surname>Millard</surname><given-names>GM</given-names></name><name><surname>Fraser</surname><given-names>NS</given-names></name><name><surname>Roots</surname><given-names>NM</given-names></name><etal/></person-group>
<article-title>Frequency of Mi<sup>a</sup> (MNS7) and classification of Mi<sup>a</sup>-positive hybrid glycophorins in an Australian blood donor population</article-title>
<source>Transfus Med Hemother</source>
<year>2020</year>
<volume>47</volume>
<fpage>279</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1159/000504026</pub-id>
<pub-id pub-id-type="pmid">32884500</pub-id>
</element-citation>
      </ref>
      <ref id="b25-blt-22-198">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandanyingyong</surname><given-names>D</given-names></name><name><surname>Pejrachandra</surname><given-names>S</given-names></name></person-group>
<article-title>Studies on the Miltenberger complex frequency in Thailand and family studies</article-title>
<source>Vox Sang</source>
<year>1975</year>
<volume>28</volume>
<fpage>152</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1111/j.1423-0410.1975.tb02753.x</pub-id>
<pub-id pub-id-type="pmid">1114793</pub-id>
</element-citation>
      </ref>
      <ref id="b26-blt-22-198">
        <label>26</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>M</given-names></name><name><surname>Lomas-Francis</surname><given-names>C</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name></person-group>
<collab>The Blood Group</collab>
<source>Antigen Factsbook</source>
<edition>3rd ed</edition>
<publisher-loc>London</publisher-loc>
<publisher-name>Elsevier Academic Press</publisher-name>
<year>2012</year>
</element-citation>
      </ref>
      <ref id="b27-blt-22-198">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandanayingyong</surname><given-names>D</given-names></name><name><surname>Pejrachandra</surname><given-names>S</given-names></name><name><surname>Poole</surname><given-names>J</given-names></name></person-group>
<article-title>Three antibodies of the MNSs system and their association with the Miltenberger Complex of antigens. I. Anek serum</article-title>
<source>Vox Sang</source>
<year>1977</year>
<volume>32</volume>
<fpage>272</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1111/j.1423-0410.1977.tb00643.x</pub-id>
<pub-id pub-id-type="pmid">855261</pub-id>
</element-citation>
      </ref>
      <ref id="b28-blt-22-198">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>CA</given-names></name><name><surname>Lin</surname><given-names>JA</given-names></name><name><surname>Chang</surname><given-names>CW</given-names></name><name><surname>Wu</surname><given-names>KH</given-names></name><name><surname>Yeh</surname><given-names>SP</given-names></name><name><surname>Ho</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Selection of GP. Mur antigen-negative RBC for blood recipients with anti-&#x2019;Mi<sup>a</sup> &#x2018; records decreases transfusion reaction rates in Taiwan</article-title>
<source>Transfus Med</source>
<year>2016</year>
<volume>26</volume>
<fpage>349</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.1111/tme.12357</pub-id>
<pub-id pub-id-type="pmid">27634577</pub-id>
</element-citation>
      </ref>
      <ref id="b29-blt-22-198">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mak</surname><given-names>KH</given-names></name><name><surname>Banks</surname><given-names>JA</given-names></name><name><surname>Lubenko</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>KM</given-names></name><name><surname>Torres de Jardine</surname><given-names>AL</given-names></name><name><surname>Yan</surname><given-names>KF</given-names></name></person-group>
<article-title>A survey of the incidence of Miltenberger antibodies among Hong Kong Chinese blood donors</article-title>
<source>Transfusion</source>
<year>1994</year>
<volume>34</volume>
<fpage>238</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1046/j.1537-2995.1994.34394196622.x</pub-id>
<pub-id pub-id-type="pmid">8146897</pub-id>
</element-citation>
      </ref>
      <ref id="b30-blt-22-198">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lomas-Francis</surname><given-names>C</given-names></name></person-group>
<article-title>Miltenberger phenotypes and glycophorin variants: a review</article-title>
<source>ISBT Sci Ser</source>
<year>2011</year>
<volume>6</volume>
<fpage>296</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1111/j.1751-2824.2011.01503.x</pub-id>
</element-citation>
      </ref>
      <ref id="b31-blt-22-198">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chandanayingyong</surname><given-names>D</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name></person-group>
<article-title>Studies on anti-Mi-a and the MiIII complex</article-title>
<source>Vox Sang</source>
<year>1975</year>
<volume>29</volume>
<fpage>311</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1111/j.1423-0410.1975.tb00513.x</pub-id>
<pub-id pub-id-type="pmid">1173702</pub-id>
</element-citation>
      </ref>
      <ref id="b32-blt-22-198">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oda</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Isa</surname><given-names>K</given-names></name><name><surname>Ogasawara</surname><given-names>K</given-names></name><name><surname>Yabe</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>GP.MOT: a novel glycophorin variant identified in a Japanese blood donor</article-title>
<source>Transfusion</source>
<year>2021</year>
<volume>61</volume>
<fpage>2825</fpage>
<lpage>2829</lpage>
<pub-id pub-id-type="doi">10.1111/trf.16535</pub-id>
<pub-id pub-id-type="pmid">34369596</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="f1-blt-22-198">
      <label>Figure 1</label>
      <caption>
        <p>Differences in nucleotide positions of <italic>GYPA</italic>, <italic>GYPB</italic>, and <italic>GYP(B-A-B)</italic> hybrids</p>
        <p>The blue and green highlights demonstrate the <italic>GYPA</italic> nucleotides inserted into <italic>GYPB</italic> pseudoexon 3 sequences. Minimum (light green highlight) and maximum (dark green highlight) sequences are identified between the breakpoint boundaries in intron 3. Red letter indicates a SNP (rs34498102) of <italic>GYP*Kip</italic> allele. The SNP encoded by exon 4 at c.236T/C (analogous to the <italic>GYPB*S</italic>/<italic>GYPB*s</italic> defining <italic>GYPB</italic> c.143T/C) identifies <italic>GYP*Hop</italic> (c.236T) from the <italic>GYP*Bun</italic> and <italic>GYP*Kip</italic> (c.236C).</p>
      </caption>
      <graphic xlink:href="BLT-22-198_g001" position="float"/>
    </fig>
    <table-wrap position="float" id="tI-blt-22-198">
      <label>Table I</label>
      <caption>
        <p>Frequencies of predicted Mi<sup>a</sup>, S and s antigens using PCR-SSP</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th rowspan="2" valign="top" align="left" colspan="1">Phenotype</th>
            <th colspan="2" valign="top" align="center" rowspan="1">PCR-SSP</th>
            <th rowspan="2" valign="top" align="center" colspan="1">No. (%)</th>
            <th rowspan="2" valign="top" align="center" colspan="1">Phenotype</th>
            <th colspan="2" valign="top" align="center" rowspan="1">PCR-SSP</th>
            <th rowspan="2" valign="top" align="center" colspan="1">No. (%)</th>
          </tr>
          <tr>
            <th valign="top" align="center" rowspan="1" colspan="1">
<italic>GYP*Vw</italic>
</th>
            <th valign="top" align="center" rowspan="1" colspan="1">
<italic>GYP*Hut, GYP*Mur, GYP*Hop, GYP*Bun and GYP*HF</italic>
</th>
            <th valign="top" align="center" rowspan="1" colspan="1">
<italic>GYPB*S</italic>
</th>
            <th valign="top" align="center" rowspan="1" colspan="1">
<italic>GYPB*s</italic>
</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="3" valign="top" align="left" colspan="1">
<bold>Mi(a+)</bold>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="center" rowspan="1" colspan="1">127 (12.45)</td>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>S+s&#x2212;</bold>
</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="right" rowspan="1" colspan="1">0 (0.00)</td>
          </tr>
          <tr>
            <td valign="top" align="center" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>S&#x2212;s+</bold>
</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="right" rowspan="1" colspan="1">124 (97.64)</td>
          </tr>
          <tr>
            <td valign="top" align="center" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>S+s+</bold>
</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="left" rowspan="1" colspan="1">Positive</td>
            <td valign="top" align="right" rowspan="1" colspan="1">3 (2.36)</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Mi(a&#x2212;)</bold>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="top" align="center" rowspan="1" colspan="1">893 (87.55)</td>
            <td colspan="3" valign="top" align="left" rowspan="1">
<bold>Total</bold>
</td>
            <td valign="top" align="right" rowspan="1" colspan="1">
<bold>127 (100.00)</bold>
</td>
          </tr>
          <tr>
            <td colspan="3" valign="top" align="left" rowspan="1">
<bold>Total</bold>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">
<bold>1,020 (100.00)</bold>
</td>
            <td colspan="4" valign="top" align="left" rowspan="1"/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tII-blt-22-198">
      <label>Table II</label>
      <caption>
        <p>Distribution of GYP(B-A-B) hybrid alleles in the Thai population</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th valign="top" align="left" rowspan="1" colspan="1">Genotype</th>
            <th valign="top" align="center" rowspan="1" colspan="1">Genotype frequency No.=1,020 (%)</th>
            <th valign="top" align="left" rowspan="1" colspan="1">Allele</th>
            <th valign="top" align="center" rowspan="1" colspan="1">Allele frequency No.=2,040 (%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYPB/GYPB</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">893 (87.55)</td>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYPB</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1,909 (93.58)</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Mur/GYPB</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">111 (10.88)</td>
            <td valign="middle" rowspan="2" align="left" colspan="1">
<bold>
<italic>GYP*Mur</italic>
</bold>
</td>
            <td valign="middle" rowspan="2" align="center" colspan="1">119 (5.83)</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Mur/GYP*Mur</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">4 (0.39)</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Thai/GYPB</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">11 (1.08)</td>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Thai</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">11 (0.54)</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Thai II/GYPB</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1 (0.10)</td>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<bold>
<italic>GYP*Thai II</italic>
</bold>
</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1 (0.05)</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tIII-blt-22-198">
      <label>Table III</label>
      <caption>
        <p>Estimation of the risk for Mi<sup>a</sup> alloimmunization among Thai and other Asian populations</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th rowspan="2" valign="top" align="left" colspan="1">Population<sup>ref</sup></th>
            <th rowspan="2" valign="top" align="center" colspan="1">No.</th>
            <th colspan="2" valign="top" align="center" rowspan="1">Predicted Mi<sup>a</sup> phenotype frequency</th>
            <th rowspan="2" valign="top" align="center" colspan="1">Risk of Mi<sup>a</sup> alloimmunization</th>
          </tr>
          <tr>
            <th valign="top" align="center" rowspan="1" colspan="1">Negative</th>
            <th valign="top" align="center" rowspan="1" colspan="1">Positive</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Thai (this study)</bold>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1,020</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.875</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.125</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.109</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Northern Thai</bold>
<xref rid="b10-blt-22-198" ref-type="bibr">10</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">300</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.777</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.223</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.173</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Southern Thai</bold>
<xref rid="b13-blt-22-198" ref-type="bibr">13</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">400</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.953</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.047</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.045</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Central Thai</bold>
<xref rid="b9-blt-22-198" ref-type="bibr">9</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1,041</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.910</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.090</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.082</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Vietnamese</bold>
<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">160</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.938</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.062</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.058</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Taiwanese</bold>
<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">167</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.958</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.042</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.040</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Indonesian</bold>
<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">285</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.982</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.018</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.018</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Filipino</bold>
<xref rid="b21-blt-22-198" ref-type="bibr">21</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">262</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.924</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.076</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.070</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Southern Han Chinese</bold>
<xref rid="b22-blt-22-198" ref-type="bibr">22</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">3,104</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.935</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.065</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.061</td>
          </tr>
          <tr>
            <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Chinese (Guangzhou)</bold>
<xref rid="b23-blt-22-198" ref-type="bibr">23</xref>
</td>
            <td valign="top" align="center" rowspan="1" colspan="1">528</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.903</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.097</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.088</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>